Yumanity Therapeutics (Yumanity Therapeutics) ROE % Adjusted to Book Value : -64.32% (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics ROE % Adjusted to Book Value?

Yumanity Therapeutics's ROE % for the quarter that ended in Sep. 2022 was -200.69%. Yumanity Therapeutics's PB Ratio for the quarter that ended in Sep. 2022 was 3.12. Yumanity Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2022 was -64.32%.

Yumanity Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Yumanity Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics ROE % Adjusted to Book Value Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

ROE % Adjusted to Book Value

-73.97

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROE % Adjusted to Book Value	Get a 7-Day Free Trial							-33.00	-111.06	-218.78	-79.29	-64.32

Competitive Comparison of Yumanity Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Yumanity Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yumanity Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's ROE % Adjusted to Book Value falls into.

Yumanity Therapeutics ROE % Adjusted to Book Value Calculation

Yumanity Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2021 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-99.12%	/	1.34
	=	-73.97%

Yumanity Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-200.69%	/	3.12
	=	-64.32%

Yumanity Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (Yumanity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (NAS:YMTX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Executives

Shawn Iadonato	director, officer: Chief Executive Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips	officer: President	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Raymond J. Bartoszek	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker	officer: Chief Financial Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny	officer: General Counsel	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux	officer: Chief Scientific Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Richard Peters	director, officer: President & CEO	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Devin Whittemore Smith	officer: SVP and General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Marie Epstein	officer: Principal Accounting Officer	C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Michael D Wyzga	officer: See Remarks	C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Paulash Mohsen	officer: Chief Business Officer	C/O YUMANITY THERAPEUTICS, INC., 40 GUESS STREET SUITE 4410, BOSTON MA 02135
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma	officer: EVP, Head of R&D	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
N Anthony Coles	director, officer: Executive Chair	MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054